title: New targets and inhibitors of HBV replication to combat drug resistance.
abstract: All the approved chemotherapeutic drugs for the treatment of HBV hepatitis are nucleoside analogs targeting on HBV DNA polymerase. Drugs targeting on other viral unique targets are needed. A new class of chemicals with novel action against HBV replication was discovered. A brief description of their mode of action is given.
authors.affiliation: Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, SHM B254, New Haven, CT 06510, USA. yccheng@yale.edu
authors.forename: Yung-Chi
authors.initials: YC
authors.lastname: Cheng
authors.forename: Chun-Xiao
authors.initials: CX
authors.lastname: Ying
authors.forename: Chung-Hang
authors.initials: CH
authors.lastname: Leung
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
mesh_terms: D000998:Antiviral Agents / Q000138:chemical synthesis / Q000494:pharmacology; D004279:DNA, Viral / Q000096:biosynthesis; D015195:Drug Design; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D017705:Lignans; D008826:Microbial Sensitivity Tests; D019384:Nucleic Acid Synthesis Inhibitors; D014779:Virus Replication / Q000187:drug effects*; D014970:Xanthines / Q000494:pharmacology
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D017705:Lignans; D019384:Nucleic Acid Synthesis Inhibitors; D014970:Xanthines; C505802:helioxanthin